Circulating Glucagon-Like Peptide-1 Level in Patients With Liver Cirrhosis Publisher Pubmed



Nourivaskeh M^{1, 2} ; Khalili N³ ; Khalaji A⁴ ; Behnam P⁵ ; Alizadeh L⁴ ; Ebrahimi S⁴ ; Gilani N⁶ ; Mohammadi M^{7, 8} ; Madinehzadeh SA⁴ ; Zarei M^{9, 10}
Source: Archives of Physiology and Biochemistry Published:2023

Abstract

Background: Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis is not clearly defined. This study aimed to investigate circulating levels of GLP-1 in liver cirrhosis and its association with the severity of liver disease. Methods: A total of 80 participants including 39 patients with a definite diagnosis of liver cirrhosis and 41 healthy controls recruited in this cross-sectional study. Circulating levels of GLP-1 were determined using the ELISA method. The severity of liver cirrhosis was assessed according to the Child-Pugh, MELD (i), MELD-Na, MELD New, and UK end-stage liver disease score (UKELD) criteria. Results: The mean age of patients and healthy subjects was 42.51 ± 12.80 and 42.07 ± 10.92 years, respectively (p value =.869). The mean MELD (i), MELD-Na, MELD New, UKELD, and Child-Pugh scores were 14.36 ± 4.26, 15.26 ± 4.81, 14.74 ± 4.66, 52.33 ± 3.82, and 7.28 ± 1.50, respectively. In this study, circulating levels of GLP-1 were statistically lower in cirrhotic patients compared with healthy controls (95.26 ± 17.15 vs 111.84 ± 38.14 pg/mL; p value =.017). Conclusion: Larger prospective studies are needed to explore the incretin effect in cirrhosis patients compared with healthy individuals. © 2020 Informa UK Limited, trading as Taylor & Francis Group.